Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Humberto Vidaillet

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
American Heart Journal|April 23, 2005
Clinical factors associated with abandonment of a rate-control or a rhythm-control strategy for the management of atrial fibrillation in the AFFIRM studyAnne B Curtis, A Allen Seals, Robert E Safford, et al.
Journal of Interventional Cardiac Electrophysiology : an International Journal of Arrhythmias and Pacing|September 7, 2007
Prevalence and mortality of patients with myocardial infarction and reduced left ventricular ejection fraction in a defined community: relation to the second multicenter automatic defibrillator implantation trialParam P Sharma, Robert T Greenlee, Kelley P Anderson, et al.
The American Journal of Medicine|October 29, 2002
A population-based study of mortality among patients with atrial fibrillation or flutterHumberto Vidaillet, Juan F Granada, P o-Huang Chyou, et al.
Heart Rhythm|April 27, 2005
Alternative endpoints for mortality in studies of patients with atrial fibrillation: the AFFIRM study experienceD George Wyse, April Slee, Andrew E Epstein, et al.
Annals of Internal Medicine|November 3, 2004
Cost-effectiveness of rhythm versus rate control in atrial fibrillationDeborah A Marshall, Adrian R Levy, Humberto Vidaillet, et al.
Journal of the American College of Cardiology|December 21, 2004
A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillationDenis Roy, Brian H Rowe, Ian G Stiell, et al.
Clinical Medicine & Research|November 19, 2009
Atrial flutter versus atrial fibrillation in a general population: differences in comorbidities associated with their respective onsetRavi K Mareedu, Ihab B Abdalrahman, Kodlipet C Dharmashankar, et al.
The American Journal of Cardiology|December 4, 2014
Effect of omega-three polyunsaturated fatty acids on inflammation, oxidative stress, and recurrence of atrial fibrillationCharles Vanderbilt, Marcia Free, Jie Li, et al.
Heart (British Cardiac Society)|October 16, 2016
Kidney function and appropriateness of device therapies in adults with implantable cardioverter defibrillatorsNisha Bansal, Adam Szpiro, Frederick Masoudi, et al.
Journal of the American Heart Association|June 4, 2015
Age and sex differences in long-term outcomes following implantable cardioverter-defibrillator placement in contemporary clinical practice: findings from the Cardiovascular Research NetworkFrederick A Masoudi, Alan S Go, David J Magid, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
American Heart Journal|April 23, 2005
Clinical factors associated with abandonment of a rate-control or a rhythm-control strategy for the management of atrial fibrillation in the AFFIRM studyAnne B Curtis, A Allen Seals, Robert E Safford, et al.
Journal of Interventional Cardiac Electrophysiology : an International Journal of Arrhythmias and Pacing|September 7, 2007
Prevalence and mortality of patients with myocardial infarction and reduced left ventricular ejection fraction in a defined community: relation to the second multicenter automatic defibrillator implantation trialParam P Sharma, Robert T Greenlee, Kelley P Anderson, et al.
The American Journal of Medicine|October 29, 2002
A population-based study of mortality among patients with atrial fibrillation or flutterHumberto Vidaillet, Juan F Granada, P o-Huang Chyou, et al.
Heart Rhythm|April 27, 2005
Alternative endpoints for mortality in studies of patients with atrial fibrillation: the AFFIRM study experienceD George Wyse, April Slee, Andrew E Epstein, et al.
Annals of Internal Medicine|November 3, 2004
Cost-effectiveness of rhythm versus rate control in atrial fibrillationDeborah A Marshall, Adrian R Levy, Humberto Vidaillet, et al.
Journal of the American College of Cardiology|December 21, 2004
A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillationDenis Roy, Brian H Rowe, Ian G Stiell, et al.
Clinical Medicine & Research|November 19, 2009
Atrial flutter versus atrial fibrillation in a general population: differences in comorbidities associated with their respective onsetRavi K Mareedu, Ihab B Abdalrahman, Kodlipet C Dharmashankar, et al.
The American Journal of Cardiology|December 4, 2014
Effect of omega-three polyunsaturated fatty acids on inflammation, oxidative stress, and recurrence of atrial fibrillationCharles Vanderbilt, Marcia Free, Jie Li, et al.
Heart (British Cardiac Society)|October 16, 2016
Kidney function and appropriateness of device therapies in adults with implantable cardioverter defibrillatorsNisha Bansal, Adam Szpiro, Frederick Masoudi, et al.
Journal of the American Heart Association|June 4, 2015
Age and sex differences in long-term outcomes following implantable cardioverter-defibrillator placement in contemporary clinical practice: findings from the Cardiovascular Research NetworkFrederick A Masoudi, Alan S Go, David J Magid, et al.
Pageof 3